Weight that will not move

Educational only: This page is for general education—not personal medical advice, diagnosis, or treatment. See a licensed clinician for your situation.

Weight that stays stuck

Weight that does not change despite serious effort is a medical complaint, not a character finding. Body weight is influenced by many factors, including medications, sleep, hormones, and conditions that change how the body handles glucose. ¹ Prediabetes — glucose or A1C in an intermediate range, short of diabetes — is associated with obesity, especially fat carried in the abdomen, and with higher cardiovascular risk. ¹

None of that assigns a person a diagnosis from a story about the scale. Classification of diabetes and prediabetes uses laboratory tests: A1C, fasting glucose, or a glucose tolerance test, done with a proper method. ¹ A visit is an evaluation, not a promise of a prescription.

Food noise

Some adults describe thoughts about food that continue after eating and are not the same, to them, as ordinary hunger. “Food noise” is that description. It is not a diagnosis in diabetes or obesity guidelines.

Appetite and weight are among the effects studied for GLP-1 receptor agonist medicines used for overweight and obesity. ² Whether those medicines change food-related thoughts for a given person is not something a page can say. If intrusive eating thoughts are part of binge eating, that is its own clinical problem and is assessed in a visit, not from a label.

Insulin resistance, including a normal A1C

Type 2 diabetes is described as loss of adequate insulin secretion, often on a background of insulin resistance. ¹ Prediabetes is the term for glucose or A1C values between the normal range and diabetes. An A1C below 5.7% is the range the American Diabetes Association treats as normal for that test, not as a complete description of metabolic health. ¹

Insulin resistance itself is not diagnosed by A1C alone in the classification standard. People can have risk related to how their body handles insulin, including conditions the ADA lists as associated with insulin resistance, while their screening glucose is still outside the diabetes range. ¹ A normal A1C does not rule out insulin resistance or other metabolic problems — it is one data point, not a clean bill of metabolic health. It also isn't proof that insulin resistance is present. The distinction between a normal screening result and a normal metabolism is a clinician's to make, using history and the appropriate tests.

What a GLP-1 conversation covers

Guidelines discuss adding an anti-obesity medicine to lifestyle measures for adults who meet defined weight-related criteria and have not had an adequate response to lifestyle measures alone. The choice of medicine depends on the clinical picture, other conditions, contraindications, and what the person prefers and can access. ²

The American Gastroenterological Association’s 2022 guideline discusses that step for adults with a body mass index of 30 kg/m² or higher, or 27 kg/m² or higher when weight-related complications are also present, and lifestyle measures alone have not been enough. ² Those figures describe who the guideline was written about. This is not your result. This page does not say that a GLP-1 medicine is appropriate for the reader.

In the trials the AGA reviewed for liraglutide, gastrointestinal effects, particularly nausea and vomiting, were more common than with lifestyle measures alone, and most of those incidents were in the first four to six weeks, while the dose was increasing. ² Nausea is a reason to contact the prescribing clinician, not a home plan for changing the dose. Vomiting that will not stop, severe abdominal pain, or signs of dehydration are reasons for urgent care, not a page of tips.

Food thoughts that return after a period of quiet are a visit question. They are not proof that a medicine failed, and they are not proof of a character flaw.

References

1. American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27–S49. https://diabetesjournals.org/care/article/49/Supplement_1/S27/163926/2-Diagnosis-and-Classification-of-Diabetes
2. Grunvald E, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198–1225. https://www.gastrojournal.org/article/S0016-5085(22)01026-5/fulltext